Description du projet
Modifier notre conception des remplacements de valves cardiaques
Bien qu’elles aident les patients souffrant de maladies cardiaques, les prothèses cardiaques posent également des problèmes. Certaines valves fabriquées à partir de tissus animaux ne durent pas longtemps, tandis que d’autres contraignent les patients à prendre des médicaments à vie. Dans cette optique, le projet StreamlineValve, financé par le CER, se propose d’améliorer le flux sanguin à travers les HV polymériques (PHV), en réduisant la thrombose liée au flux. Leur conception PHV brevetée modifie les champs d’écoulement afin de minimiser les facteurs de coagulation, tel que cela a été démontré in vitro. Le projet devrait changer les conceptions: des valves durables sans médicaments à vie, implantées par des procédures transcathéter. StreamlineValve pourrait révolutionner les valves cardiaques prothétiques, accroissant la longévité, la qualité de vie et la sécurité des patients.
Objectif
Prosthetic Heart Valves (HV), both biological (BHV) and mechanical (MHV), have improved the survival rate and the quality of life of valvular heart-disease patients over the last six decades. While BHVs, taken from animal tissue, show improved hemodynamics, their durability is limited, whereas MHVs can last a patient's entire lifetime but require lifetime anticoagulation medication to reduce thrombotic complications. Future Polymeric HVs (PHV) hold the potential for enhanced durability compared to BHVs, while potentially avoiding the necessity for anticoagulation therapy that MHVs demand. However, the problem of flow-related thrombosis in PHVs remains a critical challenge.
Generally, flow-related thrombosis complications can be avoided by altering the flow field around the PHV, such as reducing vortices and circulatory hemodynamic structures as well as decreasing shear stresses which can lead to platelet activation. Inspired by passive flow control in nature and in the aerodynamics industry, where manipulation of fluid flow via a small configuration change provides large engineering benefits in swimming or flying, we aim to use a flow control strategy to optimize blood flow through PHVs. More specifically, in StreamlineValve, we present a new, patented, PHV that is designed to alter the flow field around the valve in a manner that reduces the primary factors contributing to coagulation on PHVs. We have already successfully demonstrated this concept in vitro in a modified MHV. In this PoC, we propose to extend this to the future of prosthetic valves via a flow controlled PHV that can be implanted via a simple transcatheter procedure avoiding undesired surgical procedures. Altogether, StreamlineValve represents a paradigm shift in the realm of prosthetic HVs, offering the potential to enhance valve longevity, quality of life, and patient safety.
Champ scientifique
- medical and health sciencesclinical medicineangiologyvascular diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsfluid dynamics
- medical and health sciencesclinical medicinesurgerysurgical procedures
- engineering and technologymechanical engineeringvehicle engineeringaerospace engineeringaeronautical engineering
Mots‑clés
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régime de financement
HORIZON-ERC-POC - HORIZON ERC Proof of Concept GrantsInstitution d’accueil
32000 Haifa
Israël